Whitney Ijem
Stock Analyst at Citigroup
(4.43)
# 313
Out of 5,156 analysts
124
Total ratings
48.15%
Success rate
24.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $66 → $21 | $7.36 | +185.33% | 7 | Mar 5, 2026 | |
| PASG Passage Bio | Maintains: Buy | $67 → $23 | $8.79 | +161.66% | 8 | Mar 4, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $54 → $48 | $13.89 | +245.57% | 7 | Mar 3, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $140 | $93.00 | +50.54% | 11 | Mar 2, 2026 | |
| NGNE Neurogene | Initiates: Buy | $200 | $23.60 | +747.46% | 1 | Feb 27, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $98 → $104 | $60.88 | +70.83% | 10 | Feb 26, 2026 | |
| BEAM Beam Therapeutics | Initiates: Buy | $74 | $27.62 | +167.92% | 1 | Feb 20, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $128 → $79 | $22.61 | +249.40% | 10 | Feb 18, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $411 → $441 | $460.87 | -4.31% | 10 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $415 → $429 | $323.59 | +32.58% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $43 | $13.29 | +223.55% | 3 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $0.96 | +422.14% | 7 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $204 | $136.70 | +49.23% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $0.49 | +1,535.99% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $4.59 | +205.01% | 11 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $5.11 | +95.69% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $17.64 | +750.34% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $146.63 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $8.49 | +2,726.86% | 4 | Jul 23, 2019 |
Arcturus Therapeutics Holdings
Mar 5, 2026
Maintains: Buy
Price Target: $66 → $21
Current: $7.36
Upside: +185.33%
Passage Bio
Mar 4, 2026
Maintains: Buy
Price Target: $67 → $23
Current: $8.79
Upside: +161.66%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $54 → $48
Current: $13.89
Upside: +245.57%
Rhythm Pharmaceuticals
Mar 2, 2026
Maintains: Buy
Price Target: $141 → $140
Current: $93.00
Upside: +50.54%
Neurogene
Feb 27, 2026
Initiates: Buy
Price Target: $200
Current: $23.60
Upside: +747.46%
BioMarin Pharmaceutical
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $104
Current: $60.88
Upside: +70.83%
Beam Therapeutics
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $27.62
Upside: +167.92%
Ultragenyx Pharmaceutical
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $22.61
Upside: +249.40%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Hold
Price Target: $411 → $441
Current: $460.87
Upside: -4.31%
Alnylam Pharmaceuticals
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $323.59
Upside: +32.58%
Feb 3, 2026
Maintains: Buy
Price Target: $40 → $43
Current: $13.29
Upside: +223.55%
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.96
Upside: +422.14%
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $136.70
Upside: +49.23%
Nov 21, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $0.49
Upside: +1,535.99%
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.59
Upside: +205.01%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $5.11
Upside: +95.69%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $17.64
Upside: +750.34%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $146.63
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $8.49
Upside: +2,726.86%